• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific elaboration of a concept for an application-accompanying data collection and analysis for the drug onasemnogene abeparvovec in order to prepare a decision according to §35a (3b) Social Code Book V - Rapid report]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osilodrostat (endogenous Cushing syndrome) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Naldemedine (opioid-induced constipation) - Addendum to Commission A20-45]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lung cancer screening using low-dose computed tomography]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Collagen-covered and periosteum-covered autologous chondrocyte implantation in the knee joint as well as matrix-associated autologous chondrocyte implantation in the knee joint]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for amputations in diabetic foot syndrome - Rapid Report]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talazoparib (breast cancer) - Addendum to Commission A20-48]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifarotene (acne vulgaris) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for heart transplantations in adults - Rapid Report]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glasdegib (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [homozygous for the F508del mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bulevirtide (chronic hepatitis delta virus infection) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [heterozygous for F508del and MF mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alpelisib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Information for health insurance fund members on prenatal testing]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ozanimod (multiple sclerosis) - Addendum to Commission A20-59]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sleep position therapy for obstructive sleep apnoea]
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sleep position therapy for obstructive sleep apnoea - Addendum to commission E20-07]
2020 Health Information and Quality Authority (HIQA) Evidence summary for natural history of COVID-19 in children
2020 Health Information and Quality Authority (HIQA) Evidence summary for average length of stay in the intensive care unit for COVID-19
2020 Health Information and Quality Authority (HIQA) Evidence summary for COVID-19 clinical samples
2020 Health Information and Quality Authority (HIQA) Evidence summary for asymptomatic transmission of COVID-19
2020 Health Information and Quality Authority (HIQA) Rapid health technology assessment of alternative diagnostic testing approaches for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
2020 Health Information and Quality Authority (HIQA) Evidence summary of placental transfer of antibodies
2020 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of depression with transcranial magnetic stimulation using an H-coil (dTMS)
2020 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Paediatric cardiac surgery - literature review
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Amnion membrane for topical treatment of ophthalmic disorders, wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Alpha-1-antitrypsin genotyping
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) PSMA PET/CT imaging for informing treatment of patients with prostate cancer
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Arthroscopic injection of a bioadhesive hydrogel implant (JointRep), in conjunction with microfracture, for treatment of osteochondral defects of the knee
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Amnion membrane for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) 3D printing applications in healthcare
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Technologies for the diagnosis of prostate cancer
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Thoracic and abdominal endovascular repair
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Simulation-based education in surgery: cost-effectiveness and resource use
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vertebroplasty or kyphoplasty in patients with symptomatic osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) The treatment of primary hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Chondroitin sulfate in osteoarthritis
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Subacromial decompression for rotator cuff disease
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vertebroplasty or kyphoplasty in patients with symptomatic osteoporotic vertebral compression fractures unresponsive to non-surgical treatment [HTA scoping report protocol]
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Intrauterine ultrasound-guided radiofrequency ablation
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Moving on from 2020 and looking forward to 2021 with a new and continuous publication model
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) ASERNIP-S: unusual acronym, outstanding results
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Personal protective equipment and evidence-based advice for surgical departments during COVID-19
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Surgery triage during the COVID-19 pandemic
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Screening and testing for COVID-19 before surgery
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Safe surgery during the coronavirus disease 2019 crisis
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Surgery triage: responding to the COVID-19 pandemic. A rapid review comissioned by RACS
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Guidelines for safe surgery: open versus laparoscopic. A rapid review commissioned by RACS
2020 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Guidelines for personal protective equipment. A rapid review comissioned by RACS
2020 Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Kaiku Health Service for symptom management of cancer patients
2020 Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Indego Exoskeleton for walking rehabilitation
2020 Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Lokomat robot for walking rehabilitation
2020 Agency for Healthcare Research and Quality (AHRQ) Care interventions for people living with dementia and their caregivers
2020 Agency for Healthcare Research and Quality (AHRQ) Characteristics of existing asthma self-management education packages
2020 Agency for Healthcare Research and Quality (AHRQ) Diagnosis and treatment of clinical Alzheimer's-type dmentia
2020 Agency for Healthcare Research and Quality (AHRQ) Impact of community health worker certification on workforce and service delivery for asthma and other selected chronic diseases
2020 Agency for Healthcare Research and Quality (AHRQ) Interventions for breathlessness in patients with advanced cancer
2020 Agency for Healthcare Research and Quality (AHRQ) Interventions for substance use disorders in adolescents: a systematic review
2020 Agency for Healthcare Research and Quality (AHRQ) Labor dystocia
2020 Agency for Healthcare Research and Quality (AHRQ) Management of colonic diverticulitis
2020 Agency for Healthcare Research and Quality (AHRQ) Management of primary headaches in pregnancy
2020 Agency for Healthcare Research and Quality (AHRQ) No-touch modalities for disinfecting patient rooms in acute care settings: a rapid review
2020 Agency for Healthcare Research and Quality (AHRQ) Nonopioid pharmacologic treatments for chronic pain
2020 Agency for Healthcare Research and Quality (AHRQ) Opioid treatments for chronic pain
2020 Agency for Healthcare Research and Quality (AHRQ) Prevention, diagnosis, and management of opioids, opioid misuse, and opioid use disorder in older adults
2020 Agency for Healthcare Research and Quality (AHRQ) Resource allocation and pandemic response: an evidence synthesis to inform decision making
2020 Agency for Healthcare Research and Quality (AHRQ) Retention strategies for medications for addiction treatment in adults with opioid use disorder
2020 Agency for Healthcare Research and Quality (AHRQ) Strategies for patient, family, and caregiver engagement
2020 Agency for Healthcare Research and Quality (AHRQ) Therapies for clinically localized prostate cancer